

ABSTRACT

It is known that $\text{Ti}(\text{deferasirox})_2$, a highly cytotoxic chemical transferrin mimetic $\text{Ti}(\text{IV})$ -based compound, displays one of the highest aqueous stabilities in the $\text{Ti}(\text{IV})$ -based anticancer field. Previous metal displacement kinetic studies show that, in approximating STf (serum transferrin) binding of $\text{Fe}(\text{III})$, deferasirox favors $\text{Fe}(\text{III})$ binding versus $\text{Ti}(\text{IV})$ and can rapidly bind $\text{Fe}(\text{III})$ via a transmetalation process and could eventually result in the delivery of $\text{Ti}(\text{IV})$ to intracellular target sites on a physiologically relevant time scale. This induced dissociation of $\text{Ti}(\text{IV})$ is only observed with a labile $\text{Fe}(\text{III})$ source, which implies that $[\text{Ti}(\text{deferasirox})_2]^{2-}$ should survive intact transport into cells and become activated intracellularly. The research interest and focus has been to conduct metal-ligand competition studies to further understand the kinetic and binding affinity of deferasirox with not only $\text{Ti}(\text{IV})$ and $\text{Fe}(\text{III})$, but with other metal sources such as $\text{Cu}(\text{II})$ and $\text{Zn}(\text{II})$. With the use of external programs such as ReactLab, it will be possible to perform data fitting and deconvolution of experimental data to then be able to understand the affinity of deferasirox with the different metals.